A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy (PALETTE).

Trial Profile

A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy (PALETTE).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Leiomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PALETTE
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Sep 2017 Results (n=333) of EORTC62043 and EORTC62072 trials assessing evolution in neutrophil to lymphocyte ratio in patients with advanced soft tissue sarcoma, presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results of a pooled analysis from EORTC 62012,EORTC62043 EORTC 62072 and EORTC62091 trials presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results of a subgroup analysis assessing the effect of age, prior lines of therapy, and dose modifications on the safety and efficacy of pazopanib in advanced soft tissue carcinoma, presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top